Research dossier
Clinical research on Lithium
6 trials reviewed across 3 indications.
Strongest evidence
Mood and cognition (low-dose)
Mechanism
Lithium inhibits glycogen synthase kinase 3 beta (GSK-3β), modulates inositol signaling, and may affect BDNF and neurogenesis. The mechanism is well-characterized at pharmaceutical doses; whether 1 to 5 mg of elemental lithium engages these pathways meaningfully is unclear.
The case for low-dose lithium supplementation rests on ecological studies of drinking-water lithium and suicide rates — Japan, Austria, Texas, and others. These are observational and cannot establish that taking 5 mg of lithium orotate produces equivalent effects. There are no controlled trials of low-dose supplemental lithium for mood or cognition in healthy adults.
The pharmaceutical lithium evidence base for bipolar disorder and suicide reduction is strong, but those doses are 100 times larger than supplement doses and require serum monitoring. Supplement-dose evidence is preliminary observational data, not controlled trials.
Trials cited
Drinking-water lithium and suicide rates in Japan
positive · Observational
Ohgami et al., 2009, British Journal of Psychiatryn=1206174Ecological study across 18 Japanese municipalities found higher trace lithium levels in drinking water (0.7 to 59 µg/L) were associated with lower suicide rates. The most-cited result behind the 'low-dose lithium for mood' supplement narrative.
Ecological observational data, not a controlled trial. Confounding by socioeconomic, geographic, and demographic factors is substantial. Generated a hypothesis; did not test it.
Drinking-water lithium and suicide in Austria
positive · Observational
Kapusta et al., 2011, British Journal of Psychiatryn=6460Examined suicide rates across 99 Austrian districts in relation to drinking-water lithium concentrations. Districts with higher trace lithium showed lower suicide rates after adjustment for socioeconomic variables.
Observational replication of the Ohgami signal in a Western population. Still ecological; still not a controlled trial.
Lithium in drinking water and suicide — meta-analysis
mixed · Meta-analysis
Memarian et al., 2017, British Journal of PsychiatryMeta-analysis of ecological studies linking drinking-water lithium to suicide rates. Pooled effect was a modest inverse association. Authors emphasized that ecological-level findings cannot establish individual-level causation.
Pooled observational, ecological data only. The signal is consistent across regions but does not establish that taking a lithium supplement reduces individual suicide risk.
Lithium in drinking water and violent crime in Texas counties
positive · Observational
Schrauzer and Shrestha, 1990, Biological Trace Element ResearchEarlier ecological study across 27 Texas counties associated higher drinking-water lithium with lower rates of suicide, homicide, and arrests for narcotics offenses. One of the original observations that prompted later drinking-water lithium research.
Older ecological data with substantial confounding potential. Generated the hypothesis; did not establish causation.
Mood stabilization (low-dose)
Mechanism
Lithium modulates monoamine signaling and inositol turnover. Pharmaceutical lithium is the most consistent mood stabilizer in psychiatry; whether trace amounts replicate the effect at any meaningful level is not established.
Anecdotal and ecological data suggest trace lithium intake may track with reduced suicide rates and possibly with calmer mood, but no controlled trial of supplemental lithium orotate has tested this in healthy adults. Treating low-dose lithium as a mood stabilizer is extrapolating from drinking-water statistics, not data on the supplement itself.
Anyone with a mood disorder should be working with a psychiatrist, not self-medicating with supplemental lithium.
Drinking-water lithium and suicide rates in Japan
positive · Observational
Ohgami et al., 2009, British Journal of Psychiatryn=1206174Ecological study across 18 Japanese municipalities found higher trace lithium levels in drinking water (0.7 to 59 µg/L) were associated with lower suicide rates. The most-cited result behind the 'low-dose lithium for mood' supplement narrative.
Ecological observational data, not a controlled trial. Confounding by socioeconomic, geographic, and demographic factors is substantial. Generated a hypothesis; did not test it.
Lithium in drinking water and suicide — meta-analysis
mixed · Meta-analysis
Memarian et al., 2017, British Journal of PsychiatryMeta-analysis of ecological studies linking drinking-water lithium to suicide rates. Pooled effect was a modest inverse association. Authors emphasized that ecological-level findings cannot establish individual-level causation.
Pooled observational, ecological data only. The signal is consistent across regions but does not establish that taking a lithium supplement reduces individual suicide risk.
Longevity and aging
Mechanism
Animal studies show low-dose lithium extends lifespan in C. elegans and Drosophila. Some human ecological data link drinking-water lithium to all-cause mortality patterns. The connection between worm longevity and human supplementation is speculative.
There is a small but interesting body of model-organism data showing low-dose lithium extends lifespan in invertebrates. Human data is limited to ecological associations and no controlled trial has tested supplemental lithium for longevity endpoints.
Longevity claims for low-dose lithium rest on worms, flies, and population-level statistics. Treat them as preliminary, not actionable.
Drinking-water lithium and suicide rates in Japan
positive · Observational
Ohgami et al., 2009, British Journal of Psychiatryn=1206174Ecological study across 18 Japanese municipalities found higher trace lithium levels in drinking water (0.7 to 59 µg/L) were associated with lower suicide rates. The most-cited result behind the 'low-dose lithium for mood' supplement narrative.
Ecological observational data, not a controlled trial. Confounding by socioeconomic, geographic, and demographic factors is substantial. Generated a hypothesis; did not test it.
4 forms of Lithium compared
Lithium orotate
Reasonable; the orotate carrier is sometimes claimed to enhance brain delivery, but this claim rests on weak primary data
Best forLow-dose supplemental use marketed for mood and cognitionThe dominant retail form. Typical capsules deliver about 5 mg of elemental lithium. The case for orotate over carbonate as a 'better delivered' form is more marketing than data.
Lithium carbonate (pharmaceutical)
Well absorbed
Best forFDA-approved treatment of bipolar disorderPrescription-only in pharmaceutical doses. Standard psychiatric dosing delivers 150 to 350 mg of elemental lithium daily, with target serum levels of 0.6 to 1.2 mmol/L and routine monitoring of renal function, thyroid function, and serum levels.
Lithium aspartate
Reasonable
Best forOlder low-dose supplement formLess common than orotate in current retail. No meaningful clinical trial base.
Lithium chloride
Well absorbed
Best forResearch and historical pharmaceutical useNot a typical retail supplement. Used in some research settings.
Are you deficient? Symptoms, risk groups, lab tests
Lithium is not classified as an essential nutrient in humans. There is no established RDA, no defined deficiency state, and no validated lab marker for lithium insufficiency in healthy adults.
Common symptoms
- No clinically defined deficiency syndrome in humans
- Animal data suggests altered behavior and reproductive parameters under severe deprivation, but human relevance is unclear
Lab markers
Serum lithium
Routinely measured only in patients on pharmaceutical lithium, where target ranges are 0.6 to 1.2 mmol/L for therapy. Trace lithium from diet or supplementation typically falls far below the lower bound of standard assays.
- Therapeutic range (pharmaceutical use)
- 0.6–1.2 mmol/L
- Toxic range
- >1.5 mmol/L
Side effects and drug interactions
Side effects
Tremor
Common · Pharmaceutical doses (serum >0.6 mmol/L)
Fine hand tremor is a common pharmaceutical-dose side effect. Rare at supplemental doses.
Worse with:lithium carbonate
Thyroid dysfunction
Uncommon · Long-term pharmaceutical use
Long-term pharmaceutical lithium can cause hypothyroidism and goiter. Risk at supplemental doses appears low but has not been carefully studied.
Worse with:lithium carbonate
Renal impairment
Severe · Long-term pharmaceutical use
Long-term pharmaceutical lithium can cause nephrogenic diabetes insipidus and chronic interstitial nephritis. Not documented at supplemental doses, but the kidneys are the main route of elimination.
Worse with:lithium carbonate
GI upset and nausea
Uncommon
Reported occasionally with both pharmaceutical and supplemental lithium, particularly on an empty stomach.
Lithium toxicity
Severe · Serum >1.5 mmol/L
Tremor, confusion, ataxia, vomiting, and seizures at toxic serum levels. Almost exclusively a pharmaceutical-dose phenomenon, often triggered by dehydration, kidney impairment, or interacting medications.
Worse with:lithium carbonate
Apathy and lethargy (higher supplemental doses)
Uncommon · Reported around 150 mg/day; not expected at typical orotate doses
In open-label observation at higher supplemental doses (around 150 mg/day of lithium orotate, far above the ~5 mg elemental lithium delivered by typical retail products), apathy, listlessness, and loss of appetite have been reported. These reversed when the dose was reduced.
Drug interactions
Combined-effect risk
NSAIDs (ibuprofen, naproxen, diclofenac)NSAIDs reduce renal lithium excretion, raising serum lithium. Most clinically relevant at pharmaceutical doses.
Patients on pharmaceutical lithium need careful coordination with prescribers when adding NSAIDs.
Combined-effect risk
ACE inhibitorsangiotensin receptor blockersthiazide diureticsThese drugs reduce renal lithium clearance and can raise serum lithium into the toxic range.
Pharmaceutical lithium users on these medications need close serum monitoring. Supplemental dose risk is much lower but not zero.
Other
SSRIs and other serotonergic agentsCombination with lithium can rarely contribute to serotonin syndrome at therapeutic doses.
Generally a prescriber-managed combination at pharmaceutical doses.
Other critical caveats
- Pharmaceutical lithium for bipolar disorder is FDA-approved and well-evidenced — but at doses 50 to 100 times higher than retail orotate supplements, with mandatory renal and thyroid monitoring. Do not self-prescribe pharmaceutical-dose lithium.
- The case for low-dose supplemental lithium rests on ecological studies of drinking-water lithium, not controlled trials of supplements. The mechanism is plausible at pharmaceutical doses; whether 5 mg of elemental lithium engages it meaningfully is unclear.
- Anyone with a diagnosed mood disorder should work with a psychiatrist, not self-medicate with supplements. Lithium has narrow therapeutic windows and meaningful risk-benefit tradeoffs that demand clinical management.
- Avoid lithium during pregnancy and breastfeeding. Lithium crosses the placenta and has been associated with cardiac malformations — including Ebstein anomaly — especially in the first trimester, and it is excreted in breast milk with reported infant effects. Anyone of childbearing age considering it should discuss pregnancy planning with a clinician.
- Avoid supplemental lithium if you have cardiovascular disease, are severely debilitated, or are prone to dehydration or sodium depletion — these states raise the risk of lithium accumulation and toxicity. Maintain adequate hydration and salt intake if you do supplement.
Frequently asked
Is lithium orotate safe?
At typical retail doses of about 5 mg of elemental lithium per capsule, lithium orotate appears to be well-tolerated in healthy adults — but rigorous safety data is limited. The pharmaceutical lithium safety profile (renal, thyroid, tremor, narrow therapeutic window) is established at much higher doses. Anyone with kidney disease, thyroid disease, on NSAIDs, ACE inhibitors, ARBs, or thiazide diuretics, or with a mood disorder should consult a clinician before starting.Will lithium orotate work like prescription lithium?
No. Pharmaceutical lithium for bipolar disorder is dosed at 600 to 1,800 mg of lithium carbonate daily, delivering 150 to 350 mg of elemental lithium with target serum levels of 0.6 to 1.2 mmol/L. Lithium orotate at 5 mg of elemental lithium operates roughly 1 to 2 percent of the pharmaceutical dose. Treating it as a substitute for prescription lithium would be both ineffective and dangerous.Why does drinking-water lithium correlate with lower suicide rates?
Several ecological studies — Japan, Austria, Texas, and others — have associated higher trace lithium in tap water with lower suicide rates. The mechanism is plausible: pharmaceutical lithium is one of the strongest anti-suicide drugs in psychiatry. But ecological associations cannot establish individual-level causation, and no controlled trial has tested whether supplemental lithium reduces individual suicide risk in healthy or at-risk adults.Should I take lithium for longevity?
The longevity case rests on worm and fly studies plus ecological human data. Translating that to a recommendation for adults to take 5 mg of lithium daily for decades is a stretch. The honest read: this is preliminary, the long-term safety of low-dose lithium is not well-characterized in healthy adults, and there are higher-evidence interventions for healthy aging.How is supplemental lithium different from prescription lithium?
Dose is the dominant difference: about 5 mg of elemental lithium per supplement capsule versus 150 to 350 mg per day of prescription lithium carbonate. Form is secondary: orotate (supplement) versus carbonate (pharmaceutical). Evidence base is also different: pharmaceutical lithium has decades of randomized trials in bipolar disorder; supplemental lithium has ecological studies and animal data, not controlled trials in adults.
References
Last reviewed2026-05-07